Trial Profile

A Randomized Phase 3 Trial Evaluating the Safety & Efficacy of IP IMNN-001 Administered in Combination w/ Standard Neoadjuvant & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 28 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IMNN 001 (Primary) ; Carboplatin; Niraparib; Olaparib; Paclitaxel
Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Sarcoma
Focus Registrational; Therapeutic Use
Acronyms OVATION 3
Sponsors Imunon

30 Jul 2025 According to an Imunon media release, initiation of additional trial sites and patient enrollment activities ongoing with multiple patients in screening
30 Jul 2025 According to an Imunon media release, company announced that the first patient has been dosed in this trial.
06 Jul 2025 Planned initiation date changed from 16 Jun 2025 to 11 Jul 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com